NCT03923413

Brief Summary

The aims of this project are 1) to evaluate whether circulating micraparticals (MPs) in patients with LVAD impair endothelial function and 2) to assess the procoagulative activity of circulating MPs in patients with LVAD in a prospective longitudinal study of patients undergoing LVAD implantation, 3) to analyze these parameters in the context of thromboembolic events.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
65

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started May 2017

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2017

Completed
1.9 years until next milestone

First Submitted

Initial submission to the registry

April 12, 2019

Completed
10 days until next milestone

First Posted

Study publicly available on registry

April 22, 2019

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2019

Completed
Last Updated

June 21, 2019

Status Verified

June 1, 2019

Enrollment Period

2.1 years

First QC Date

April 12, 2019

Last Update Submit

June 19, 2019

Conditions

Keywords

circulating MPFMDLVADendothelial functionendothelial integrity

Outcome Measures

Primary Outcomes (1)

  • Occurrence of thrombemboic events during 12 month

    12 month

Secondary Outcomes (3)

  • Endothelial function

    Baseline

  • Level of circulating mircoparticles

    Baseline

  • microparticle induced thrombin generation

    Baseline

Study Arms (2)

patients with chronic heart failure without LVAD support

patients with chronic heart failure without LVAD support

Other: Blood samples

patients with end-stage heart failure with LVAD support

patients with end-stage heart failure with LVAD support

Other: Blood samples

Interventions

Blood samples for MP evaluation

patients with chronic heart failure without LVAD supportpatients with end-stage heart failure with LVAD support

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients in the heart failure program of the University of Duesseldorf

You may qualify if:

  • Patients on LVAD support

You may not qualify if:

  • current thrombembolic or bleeding event

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Heinrich-Heine-University, Div. of Cardiology, Pulmonary Disease and Vascular Medicine

Düsseldorf, North Rhine-Westphalia, 40225, Germany

Location

Related Publications (1)

  • Kramser N, Oehler D, Saeed D, Aubin H, Akhyari P, Kelm M, Westenfeld R, Horn P. Thromboembolic Events in Patients With Left Ventricular Assist Devices Are Related to Microparticle-Induced Coagulation. ASAIO J. 2021 Jan 1;67(1):59-66. doi: 10.1097/MAT.0000000000001200.

Biospecimen

Retention: SAMPLES WITHOUT DNA

3ml venous blood

MeSH Terms

Interventions

Blood Specimen Collection

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative Techniques

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr.med. Patrick Horn, Principle Investigator

Study Record Dates

First Submitted

April 12, 2019

First Posted

April 22, 2019

Study Start

May 1, 2017

Primary Completion

May 31, 2019

Study Completion

May 31, 2019

Last Updated

June 21, 2019

Record last verified: 2019-06

Locations